Paper Details

  1. Home
  2. Paper Details

A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus.

Author: , AranedaAndres, BidartTeresa, CalvoMario, CuizaAnalia, DelgadoIris, FlorenzanoMatias, GrafJerónimo, Hanfelt-GoadeDiane, HjelleBrian, MarcoClaudia, MertzGregory J, ParedesLaura, RiosecoM Luisa, RiquelmeRaul, RiveraJuan C, TomicicVinko, ValdiviesoFrancisca, VialCecilia, VialPablo A, YeChunyan

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Hantavirus cardiopulmonary syndrome (HCPS) is a severe and potentially fatal disease caused by Andes virus in Chile. This study investigates the safety and effectiveness of immune plasma as a treatment for HCPS.
Paper Details　
Original Abstract of the Article :
In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. W...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3851/IMP2875

データ提供：米国国立医学図書館（NLM）

Human Immune Plasma: A Potential Treatment for Hantavirus Cardiopulmonary Syndrome

Hantavirus cardiopulmonary syndrome (HCPS) is a severe and often fatal disease caused by hantaviruses. Currently, there is no specific treatment for HCPS, and the mortality rate remains high. This study investigates the potential of human immune plasma as a treatment strategy for HCPS caused by Andes virus (ANDV).

Human Immune Plasma Shows Promise for HCPS Treatment

The researchers conducted a non-randomized multicenter trial to assess the safety and efficacy of human immune plasma in treating ANDV-related HCPS. The study found that human immune plasma was generally safe and well-tolerated. While the study did not demonstrate a definitive improvement in survival, it provided encouraging preliminary evidence for the potential of immune plasma as a treatment option for HCPS.

Exploring New Treatment Strategies for Emerging Infectious Diseases

This study highlights the ongoing need for research to explore new treatment strategies for emerging infectious diseases like HCPS. Just as a desert traveler seeks out new sources of water in an arid landscape, scientists are constantly searching for innovative solutions to combat infectious diseases. This research provides a valuable starting point for exploring the potential of immune plasma as a treatment option for HCPS.

Dr. Camel's Conclusion

This study provides preliminary evidence for the potential of human immune plasma as a treatment for hantavirus cardiopulmonary syndrome (HCPS). While further research is needed, this study highlights the importance of exploring novel therapies for emerging infectious diseases. The search for new and effective treatment strategies for diseases like HCPS is a challenging but essential endeavor, and this research offers a glimmer of hope for patients facing this serious health threat.

Date :
  1. Date Completed 2016-04-12
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25316807

DOI: Digital Object Identifier

10.3851/IMP2875

Related Literature

Article Analysis
・Effective treatment of hantavirus infections
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.